Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
View original at finance.yahoo.comChronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
KIM-1 and NGAL enable earlier, more precise detection of CKD than traditional methods, improving the potential for timely intervention and better patient outcomes
80% confidenceThe CKD market size in the 7MM was approximately USD 4.8 billion in 2024 and is expected to increase further by 2034
80% confidenceZibotentan/dapagliflozin combination has the potential to reduce mortality and delay the onset of end-stage kidney disease (ESKD)
80% confidenceIncreasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment
80% confidenceDespite improved outcomes, current therapies only delay progression and cannot halt or reverse CKD, highlighting a major and persistent unmet need
80% confidenceCKD cases are projected to increase further over the forecast period (2025-2034) due to the aging population
80% confidenceThe chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations
80% confidenceIn 2024, there were nearly 14.5 million total diagnosed cases of CKD in the 7MM
80% confidenceThe distribution of End-Stage Kidney Disease (ESKD) cases across the 7MM indicates that the number of patients on dialysis exceeds that of those receiving kidney transplants
80% confidenceThe United States accounts for the largest market size of chronic kidney disease, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan
80% confidenceIn 2024, there were approximately 82 million prevalent cases of CKD in the 7MM
80% confidenceNo current medications can reverse CKD
80% confidenceThe CKD therapy market includes RAAS inhibitors as the standard of care and the rapidly growing use of SGLT-2 inhibitors such as FARXIGA and JARDIANCE as emerging front-line options
80% confidence